drugset / Trial / NCT04116073
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Phase 2
Completed
25 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyte Corporation · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.
Timeline
- Start
- 2020-04-09
- Primary completion
- 2024-08-06
- Completion
- 2024-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retifanlimab | Monoclonal antibody | 500 mg | Intravenous |